Stock Report

All about this stock under one free report Last Updated: 10-Nov-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Bacil Pharma Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

BSE: 524516

₹16.82

up-down-arrow ₹-0.22 (-1.29%)

As on 09-Nov-2026IST

Market cap

info icon

₹24 Cr

Revenue (TTM)

info icon

₹0 Cr

P/E Ratio

info icon

38

P/B Ratio

info icon

0.9

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -- --
EBIT -156.52 -63.89 60.78 3.47 9.15
Net Profit 43.75 -164.29 -38.05 95.52 31.53
EPS 44.35 -164.00 -32.45 62.72 23.01
Book Value -- -- -2.50 184.80 69.91
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info ----------
Net Margin info ----177.37----
Return on equity info -0.62-119.352.546.353.19
Return on Capital info 0.72-55.91--3.933.03
Return on Assets info 1.26-31.132.455.953.01
Debt to Equity (x) info ----0.000.000.01

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
--
3.93
3.03
-4.80
-8.45
Peer Median
--
14.90
14.72
18.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

2.54

Lower than Peers by 8.32

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
2.54
6.35
3.19
-11.38
-19.42
Peer Median
10.86
12.42
11.67
14.92
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

2.45

Lower than Peers by 4.27

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
2.45
5.95
3.01
-5.18
-9.37
Peer Median
6.72
7.49
7.86
9.06
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

177.37

Higher than Peers by 168.35

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
177.37
125.93
61.10
-45.29
-88.92
Peer Median
9.02
8.42
9.33
8.49
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

EBIT Growth

60.78

Higher than Peers by 42.48

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
60.78
3.20
-33.99
12.14
94.51
Peer Median
18.30
27.13
24.15
28.00
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-38.05

Lower than Peers by 56.49

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
-38.05
284.93
783.76
42.00
97.36
Peer Median
18.44
36.24
30.29
36.51
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-32.45

Lower than Peers by 43.50

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
-32.45
284.92
402.19
42.02
97.36
Peer Median
11.05
17.61
24.50
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
--
-2.50
4,204.55
24.59
-21.28
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
--
--
0.01
0.08
0.02
Peer Median
0.04
0.25
0.23
0.20
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
--
--
0.01
0.08
0.02
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

20.71

Higher than Peers by 18.99

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
20.71
0.68
17.21
0.46
8.20
Peer Median
1.72
1.82
1.79
1.96
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

20.71

Higher than Peers by 19.54

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
20.71
0.68
17.21
0.46
8.20
Peer Median
1.17
1.16
1.47
1.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
--
--
583.29
-83.43
-66.93
Peer Median
7.82
7.80
9.42
8.58
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Asset Turnover

--

--

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
--
--
--
--
--
Peer Median
0.67
0.79
0.75
0.77
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

38.02

Lower than Peers by 5.71

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
38.02
40.91
140.18
--
--
Peer Median
43.73
42.73
39.70
33.48
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

0.94

Lower than Peers by 3.39

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
0.94
2.63
2.28
14.96
6.98
Peer Median
4.34
4.55
3.72
4.21
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
--
--
--
--
--
Peer Median
0.09
0.09
0.16
0.21
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

135.45

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
135.45
63.69
131.93
-154.07
-32.95
Peer Median
--
32.67
30.23
29.90
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

24

Lower than Peers by 8,316

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bacil Pharma
24
--
--
--
--
Peer Median
8,340
5,455
4,851
2,099
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...

Informed fund ideas, better judgment. Every month. Mutual Fund Insight, every month since October 2002.

Take charge. Know more. Keep more. Mutual Fund Insight helps you do all three — every month